Real time insider trading transaction history:
- Insiders are prohibited from making short-swing profits by trading their shares within 6 months of the registration or acquiring the shares.
- Shares are not adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
Common stock purchase or sale:
| Transaction Date |
Reported DateTime |
Company | Symbol | Insider Relationship |
Shares Traded |
Average Price |
Total Amount |
Shares Owned |
Filing |
| 2024-01-31 Sale |
2024-02-02 4:29 pm |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner |
500,000 | $15 | $7,500,000 | 771,983 (Indirect) |
View |
| 2024-01-30 Sale |
2024-02-01 8:10 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
1,270 | $16.41 | $20,840 | 212,633 (Indirect Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 9:22 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $15.85 | $190,256 | 1,401,585 (Indirect Direct) |
View |
| 2024-01-29 Sale |
2024-01-31 9:20 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $15.81 | $51,388 | 245,870 (Direct) |
View |
| 2024-01-25 Sale |
2024-01-29 8:01 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $15.69 | $188,229 | 1,549,137 (Indirect Direct) |
View |
| 2024-01-22 Sale |
2024-01-24 6:38 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
4,875 | $15.13 | $73,783 | 411,249 (Indirect Direct) |
View |
| 2023-12-29 Sale |
2024-01-03 7:01 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $14.28 | $171,381 | 1,413,585 (Indirect Direct) |
View |
| 2023-12-28 Sale |
2024-01-02 8:00 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
13,540 | $15.02 | $203,348 | 416,124 (Indirect Direct) |
View |
| 2023-12-28 Sale |
2024-01-02 7:59 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
11,870 | $15.02 | $178,327 | 766,146 (Direct) |
View |
| 2023-12-26 Sale |
2023-12-28 4:29 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $14.64 | $175,709 | 1,561,137 (Indirect Direct) |
View |
| 2023-12-22 Sale |
2023-12-27 5:28 pm |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
1,085 | $15.03 | $16,306 | 429,664 (Indirect Direct) |
View |
| 2023-12-22 Sale |
2023-12-27 5:26 pm |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
1,130 | $15.07 | $17,025 | 522,080 (Direct) |
View |
| 2023-12-21 Sale |
2023-12-26 7:32 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
6,566 | $13.07 | $85,790 | 1,740,681 (Indirect Direct) |
View |
| 2023-12-21 Sale |
2023-12-26 7:31 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,195 | $13.05 | $106,915 | 1,889,862 (Indirect Direct) |
View |
| 2023-12-21 Sale |
2023-12-26 7:29 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
216 | $13 | $2,808 | 213,903 (Indirect Direct) |
View |
| 2023-12-20 Sale |
2023-12-21 4:31 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
7,779 | $13.01 | $101,238 | 1,581,332 (Indirect Direct) |
View |
| 2023-12-19 Sale |
2023-12-21 4:29 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,888 | $13.01 | $115,646 | 1,755,955 (Indirect Direct) |
View |
| 2023-12-19 Sale |
2023-12-21 4:28 pm |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
4,280 | $13.02 | $55,727 | 214,119 (Indirect Direct) |
View |
| 2023-11-03 Sale |
2023-11-06 4:43 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,546 | $13.08 | $111,751 | 1,441,039 (Indirect Direct) |
View |
| 2023-11-03 Sale |
2023-11-06 4:42 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,026 | $13.08 | $104,999 | 1,589,111 (Indirect Direct) |
View |
| 2023-09-29 Sale |
2023-10-03 7:40 pm |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $13.62 | $163,498 | 1,449,585 (Indirect Direct) |
View |
| 2023-09-26 Sale |
2023-09-28 4:27 pm |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner |
197,500 | $15 | $2,962,500 | 854,796 (Indirect) |
View |
| 2023-09-25 Sale |
2023-09-26 7:37 pm |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $13.81 | $165,691 | 1,597,137 (Indirect Direct) |
View |
| 2023-08-24 Sale |
2023-08-28 4:20 pm |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH Schwab Andrew J. 10% Owner |
440,000 | $16 | $7,040,000 | 887,507 (Indirect) |
View |
Stock options: Exercise, Award, Grant, Conversion
| Transaction Date |
Reported DateTime |
Exercisable Expiration |
Company | Symnbol | Insider Relationship |
Shares Traded |
Conversion Price |
Shares Owned |
Filing |
| 2024-01-29 Exercise |
2024-01-31 9:22 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $1.12 | 1,401,585 (Direct) |
View |
| 2024-01-29 Exercise |
2024-01-31 9:22 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P CHIEF SCIENTIFIC OFFICER |
12,000 | $0 | 1,401,585 (Direct) |
View |
| 2024-01-29 Exercise |
2024-01-31 9:20 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $0 | 245,870 (Direct) |
View |
| 2024-01-29 Exercise |
2024-01-31 9:20 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin CHIEF FINANCIAL OFFICER |
3,250 | $2.48 | 245,870 (Direct) |
View |
| 2024-01-25 Exercise |
2024-01-29 8:01 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $1.12 | 1,549,137 (Direct) |
View |
| 2024-01-25 Exercise |
2024-01-29 8:01 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $0 | 1,549,137 (Direct) |
View |
| 2023-12-29 Exercise |
2024-01-03 7:01 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $1.12 | 1,413,585 (Direct) |
View |
| 2023-12-29 Exercise |
2024-01-03 7:01 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $0 | 1,413,585 (Direct) |
View |
| 2023-12-28 Exercise |
2024-01-02 7:59 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
11,870 | $0 | 766,146 (Direct) |
View |
| 2023-12-28 Exercise |
2024-01-02 7:59 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
11,870 | $2.48 | 766,146 (Direct) |
View |
| 2023-12-26 Exercise |
2023-12-28 4:29 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $1.12 | 1,561,137 (Direct) |
View |
| 2023-12-26 Exercise |
2023-12-28 4:29 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $0 | 1,561,137 (Direct) |
View |
| 2023-12-22 Exercise |
2023-12-27 5:26 pm |
N/A 2031-08-02 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
1,130 | $0 | 522,080 (Direct) |
View |
| 2023-12-22 Exercise |
2023-12-27 5:26 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
1,130 | $2.48 | 522,080 (Direct) |
View |
| 2023-12-21 Exercise |
2023-12-26 7:32 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
6,566 | $1.12 | 1,740,681 (Direct) |
View |
| 2023-12-21 Exercise |
2023-12-26 7:32 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
6,566 | $0 | 1,740,681 (Direct) |
View |
| 2023-12-21 Exercise |
2023-12-26 7:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,195 | $1.12 | 1,889,862 (Direct) |
View |
| 2023-12-21 Exercise |
2023-12-26 7:31 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,195 | $0 | 1,889,862 (Direct) |
View |
| 2023-12-20 Exercise |
2023-12-21 4:31 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
7,779 | $1.12 | 1,581,332 (Direct) |
View |
| 2023-12-20 Exercise |
2023-12-21 4:31 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
7,779 | $0 | 1,581,332 (Direct) |
View |
| 2023-12-19 Exercise |
2023-12-21 4:29 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,888 | $1.12 | 1,755,955 (Direct) |
View |
| 2023-12-19 Exercise |
2023-12-21 4:29 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,888 | $0 | 1,755,955 (Direct) |
View |
| 2023-11-03 Exercise |
2023-11-06 4:43 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,546 | $1.12 | 1,441,039 (Direct) |
View |
| 2023-11-03 Exercise |
2023-11-06 4:43 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
8,546 | $0 | 1,441,039 (Direct) |
View |
| 2023-11-03 Exercise |
2023-11-06 4:42 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,026 | $1.12 | 1,589,111 (Direct) |
View |
| 2023-11-03 Exercise |
2023-11-06 4:42 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
8,026 | $0 | 1,589,111 (Direct) |
View |
| 2023-09-29 Exercise |
2023-10-03 7:40 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $1.12 | 1,449,585 (Direct) |
View |
| 2023-09-29 Exercise |
2023-10-03 7:40 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
12,000 | $0 | 1,449,585 (Direct) |
View |
| 2023-09-25 Exercise |
2023-09-26 7:37 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $1.12 | 1,597,137 (Direct) |
View |
| 2023-09-25 Exercise |
2023-09-26 7:37 pm |
N/A 2030-06-15 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
12,000 | $0 | 1,597,137 (Direct) |
View |
| 2023-05-17 Exercise |
2023-05-19 4:19 pm |
N/A 2032-06-01 |
Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner |
2,125 | $0 | 8,951,463 (Indirect) |
View |
| 2023-05-17 Exercise |
2023-05-19 4:19 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | ORBIMED ADVISORS LLC OrbiMed Capital GP VII LLC OrbiMed Genesis GP LLC Director 10% Owner |
2,125 | $4.28 | 8,951,463 (Indirect) |
View |
| 2023-05-17 Exercise |
2023-05-19 4:12 pm |
N/A 2032-06-01 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
2,125 | $0 | 8,951,463 (Indirect) |
View |
| 2023-05-17 Exercise |
2023-05-19 4:12 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
2,125 | $4.28 | 8,951,463 (Indirect) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:34 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Patel Anish Chief Operating Officer |
206,000 | $0 | 206,000 (Direct) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:33 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Lyssikatos Joseph P Chief Scientific Officer |
206,000 | $0 | 206,000 (Direct) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:32 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Hohl Benjamin Chief Financial Officer |
206,000 | $0 | 206,000 (Direct) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:32 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Collins Helen Louise Chief Medical Officer |
206,000 | $0 | 206,000 (Direct) |
View |
| 2023-04-04 Option Award |
2023-04-06 8:30 pm |
N/A 2033-04-04 |
Enliven Therapeutics Inc. | ELVN | Kintz Samuel President and CEO |
452,000 | $0 | 452,000 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:22 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Schwab Andrew J. Director 10% Owner |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:20 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Phillips Andrew John Director |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:19 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Heyman Richard A. Director |
34,458 | $0 | 34,458 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:18 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Gupta Rishi Director 10% Owner |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:17 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Derynck Mika K Director |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:16 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Bauer Jake Director |
27,567 | $0 | 27,567 (Direct) |
View |
| 2023-02-23 Option Award |
2023-04-06 8:15 pm |
N/A 2033-02-23 |
Enliven Therapeutics Inc. | ELVN | Ballal Rahul D. Director |
27,567 | $0 | 27,567 (Direct) |
View |
Ownership |
2023-03-06 5:18 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | 5AM Partners VI LLC 5AM Ventures VI L.P. 5AM Opportunities I (GP) LLC 5AM Opportunities I L.P. PARMAR KUSH 10% Owner |
0 | $0 | 5,798,475 (Indirect) |
View |
| 2023-02-23 Option Award |
2023-02-27 9:55 pm |
N/A N/A |
Enliven Therapeutics Inc. | ELVN | Schwab Andrew J. Director |
5,798,475 | $0 | 960,383 (Indirect) |
View |